Tag: Astrazeneca
AstraZeneca: favorable opinion in breast cancer
(CercleFinance.com) – AstraZeneca announces that its Enhertu, co-developed with Daiichi Sankyo, has been recommended by the CHMP for approval in the EU as monotherapy for the treatment of adult patients…
AstraZeneca: conclusive trial in breast cancer
(CercleFinance.com) – AstraZeneca announces that a phase III trial involving the combination of capivasertib and Faslodex (fulvestrant) showed ‘a clinically and statistically significant improvement’ in progression-free survival (PFS) in patients…
AstraZeneca: Bank of America reiterates the purchase
(CercleFinance.com) – Bank of America reiterated its buy recommendation on AstraZeneca on Wednesday, with a target price of 12,500 pence, believing that the valuation of the laboratory, its growth and…
AstraZeneca: Green light in China for Alexion treatment
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
AstraZeneca: Towards a new indication for Lynparza
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
AstraZeneca: green light in China for Alexion treatment
(CercleFinance.com) – AstraZeneca today announced the availability of the first rare disease treatment from Alexion, its rare disease subsidiary of AstraZeneca, in China. The company thus announces the availability of…
AstraZeneca: towards a new indication for Lynparza
(CercleFinance.com) – The Committee for Medicinal Products for Human Use (CHMP) announced on Friday that it had adopted a favorable opinion with a view to marketing AstraZeneca’s Lynparza in a…
AstraZeneca: green light for Imfinzi + Imjudo in the USA
(CercleFinance.com) – AstraZeneca announced Friday that the FDA has approved the use of its combination therapy Imfinzi and Imjudo in the treatment of stage 4 non-small cell lung cancer. The…
AstraZeneca: the PADAC shared on the anti-asthma inhaler
(CercleFinance.com) – AstraZeneca announces that the Food and Drug Administration’s (FDA) Pulmonary Allergy Drug Advisory Committee (PADAC) has issued a favorable evaluation (16 votes against 1) on the risk/benefit ratio…
AstraZeneca: full marketing authorization for the Covid vaccine in the EU
(CercleFinance.com) – AstraZeneca announces that its Covid vaccine, Vaxzevria, has obtained full marketing authorization (MA) in the European Union (EU) from the European Medicines Agency (EMA). ) after the EMA’s…
AstraZeneca: more than 60 abstracts planned at two congresses
(CercleFinance.com) – AstraZeneca announced on Monday that it had planned to present around sixty abstracts at two scientific congresses due to open this week. This is the congress of the…
Covid-19: a higher risk of thrombosis with the AstraZeneca vaccine
AstraZeneca’s Covid vaccine causes a 30% higher risk of thrombocytopenia than a first dose of the Pfizer-BioNTech vaccine. SourceAFP AstraZeneca’s Covid vaccine causes more cases of thrombosis than Pfizer-BioNTech’s. ©…